190 related articles for article (PubMed ID: 15061043)
1. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor.
Kolbach DN; Hamulyák K; Prins MH; Neumann HA; Cleutjens JP
Vasa; 2004 Feb; 33(1):19-24. PubMed ID: 15061043
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
3. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
Peschen M; Rogers AA; Chen WY; Vanscheidt W
Acta Derm Venereol; 2000 May; 80(3):162-6. PubMed ID: 10954203
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activation in venous leg ulcers.
Herouy Y; Trefzer D; Hellstern MO; Stark GB; Vanscheidt W; Schöpf E; Norgauer J
Br J Dermatol; 2000 Nov; 143(5):930-6. PubMed ID: 11069499
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
6. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Rogers AA; Burnett S; Lindholm C; Bjellerup M; Christensen OB; Zederfeldt B; Peschen M; Chen WY
Vasa; 1999 May; 28(2):101-5. PubMed ID: 10409920
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
9. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
Herouy Y; Aizpurua J; Stetter C; Dichmann S; Idzko M; Hofmann C; Gitsch G; Vanscheidt W; Schöpf E; Norgauer J
J Cutan Pathol; 2001 Jul; 28(6):291-7. PubMed ID: 11401675
[TBL] [Abstract][Full Text] [Related]
10. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenesis of skin pathologic changes and ulceration].
Qian HS
Zhonghua Yi Xue Za Zhi; 1993 Jun; 73(6):352-4, 381-2. PubMed ID: 8258106
[TBL] [Abstract][Full Text] [Related]
12. Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1.
Solberg A; Holmdahl L; Falk P; Willén R; Palmgren I; Ivarsson ML
Scand J Gastroenterol; 2009; 44(5):579-84. PubMed ID: 19153874
[TBL] [Abstract][Full Text] [Related]
13. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology.
Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF
J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 in neointima of vein grafts: its role in reduced fibrinolytic potential and graft failure.
Kauhanen P; Sirén V; Carpén O; Vaheri A; Lepäntalo M; Lassila R
Circulation; 1997 Sep; 96(6):1783-9. PubMed ID: 9323062
[TBL] [Abstract][Full Text] [Related]
15. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
16. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning.
van Kesteren PJ; Kooistra T; Lansink M; van Kamp GJ; Asscheman H; Gooren LJ; Emeis JJ; Vischer UM; Stehouwer CD
Thromb Haemost; 1998 May; 79(5):1029-33. PubMed ID: 9609242
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
[TBL] [Abstract][Full Text] [Related]
18. In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Pourtau J; Soria C; Paysant J; Vannier JP; Vasse M
Blood Coagul Fibrinolysis; 1998 Oct; 9(7):609-15. PubMed ID: 9863709
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.
Nosaka M; Ishida Y; Kuninaka Y; Kimura A; Kondo T
Int J Legal Med; 2012 May; 126(3):421-5. PubMed ID: 22361951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
